Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2025
0mins
Should l Buy ?
Source: Globenewswire
Presentation of Study Results: Lipella Pharmaceuticals will present its findings on LP-10, a treatment for Oral Lichen Planus (OLP), at the joint international meeting of AAOM and EAOM in Las Vegas from May 14-17, showcasing significant improvements in patients after four weeks of treatment.
Clinical Trial Insights: The Phase 2a trial indicates that LP-10, a liposomal formulation of tacrolimus, is well-tolerated and shows potential as a non-steroidal therapeutic option for OLP, with visible lesion resolution and statistically significant clinical improvements noted during the study.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
